Ganbold et al. (2019) reported that ISO could alleviate steatosis and fibrosis in a non-alcoholic steatohepatitis (NASH) mouse model by reducing the expression of liver injury marker transforming growth factor β (Tgfβ), and the fibrogenic marker Collagen type I alpha 1 (Col1a1). However, little is known about the possible protective effect of ISO against cardiac fibrosis or hypertrophy (Gao et al., 2017). This evidence concerns the gene COL1A1 and steatosis.